Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The international intravitreal bevacizumab safety survey.

Literature DB >> 17057183

The international intravitreal bevacizumab safety survey.

F Ziemssen, S Grisanti, K U Bartz-Schmidt.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2006 PMID： 17057183 PMCID： PMC1857465

Source DB: PubMed Journal: Br J Ophthalmol ISSN： 0007-1161 Impact factor: 4.638

× No keyword cloud information.

11 in total

Review 1. Detecting adverse events using information technology.

Authors: David W Bates; R Scott Evans; Harvey Murff; Peter D Stetson; Lisa Pizziferri; George Hripcsak
Journal: J Am Med Inform Assoc Date: 2003 Mar-Apr Impact factor: 4.497

Review 2. The quality of published adverse drug event reports.

Authors: William N Kelly
Journal: Ann Pharmacother Date: 2003-12 Impact factor: 3.154

Review 3. Measurement and expression of risk: optimizing decision strategies.

Authors: E Jan Irvine
Journal: Am J Med Date: 2004-09-06 Impact factor: 4.965

4. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report.

Authors: A K Jha; G J Kuperman; J M Teich; L Leape; B Shea; E Rittenberg; E Burdick; D L Seger; M Vander Vliet; D W Bates
Journal: J Am Med Inform Assoc Date: 1998 May-Jun Impact factor: 4.497

5. Influence of physicians' attitudes on reporting adverse drug events: a case-control study.

Authors: A Figueiras; F Tato; J Fontaiñas; J J Gestal-Otero
Journal: Med Care Date: 1999-08 Impact factor: 2.983

6. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment.

Authors: J C Sinclair; R J Cook; G H Guyatt; S G Pauker; D J Cook
Journal: J Clin Epidemiol Date: 2001-03 Impact factor: 6.437

The international intravitreal bevacizumab safety survey.

Review 1. Detecting adverse events using information technology.

Review 2. The quality of published adverse drug event reports.

Review 3. Measurement and expression of risk: optimizing decision strategies.

4. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report.

5. Influence of physicians' attitudes on reporting adverse drug events: a case-control study.

6. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment.

7. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.

Review 8. Masked hypertension: how can the condition be detected?

Review 9. Detecting adverse events for patient safety research: a review of current methodologies.

Review 10. Follow-up by mail in clinical trials: does questionnaire length matter?

1. Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema.

Review 2. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?